HR 328 109th Congress House Health Administrative fees Administrative procedure Administrative remedies Business records Civil actions and liability Commerce Congress Congressional reporting requirements Consumer education Consumer protection Damages Department of Health and Human Services Drug approvals Drug industry Drugs Economics and Public Finance Electronic government information Evidence (Law) Federal Trade Commission

Pharmaceutical Market Access Act of 2005

Introduced: January 25, 2005 See on congress.gov

Everywhere this bill has been 11 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Jun 21, 2005

Sponsor introductory remarks on measure. (CR H4861)

Jun 20, 2005

Sponsor introductory remarks on measure. (CR H4784-4785)

May 17, 2005

Sponsor introductory remarks on measure. (CR H3406-3407)

May 16, 2005

Sponsor introductory remarks on measure. (CR H3289-3290)

Apr 13, 2005

Sponsor introductory remarks on measure. (CR H1945-1946)

Apr 5, 2005

Sponsor introductory remarks on measure. (CR H1754)

Mar 2, 2005

Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.

Feb 25, 2005

Referred to the Subcommittee on Health.

Feb 15, 2005

Sponsor introductory remarks on measure. (CR H606)

Jan 25, 2005

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Jan 25, 2005

Introduced in House

Plain-English summary Congressional Research Service

Pharmaceutical Market Access Act of 2005 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services to promulgate regulations permitting pharmacists, pharmacies, wholesalers, and individuals to import qualifying drugs from certain countries into the United States.

Sets forth registration requirements for exporters.

Requires the Secretary to: (1) educate consumers with regard to the availability of qualifying drugs for import for personal use; (2) inspect the facilities and records of importers and registered exporters to ensure compliance with this Act; and (3) establish a registration fee program to collect an annual fee from registered exporters.

Deems a prescription drug to be misbranded unless the packaging of such drug complies with the requirements for counterfeit-resistant technologies.

Prohibits: (1) failing to register in accordance with this Act; and (2) importing or offering to import a prescription drug in violation of a suspension order.

Declares that selling or importing a patented drug in the United States that was first sold abroad by or under authority of the owner or licensee of the patent is not patent infringement.

Prohibits drug manufacturers from discriminating against a person that engages in the importation of a prescription drug, including by charging higher prices or denying supplies of the drug.

Allows the Secretary to suspend or terminate the registration of an exporter for failing to maintain substantial compliance with all registration conditions.

What's happening now June 21, 2005

Sponsor introductory remarks on measure. (CR H4861)

Committees of jurisdiction 4